ARS Pharmaceuticals, Inc. (SPRY)
SPRY moved a median of -0.25% 30 minutes after news, and -0.46% by the close. How SPRY actually reacts to news — the realized, point-in-time move the market made, measured across 1,121 labeled events over the last three years with zero look-ahead.
SPRY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 43% | 1,099 |
| 30-min | -0.25% | 44% | 1,101 |
| 60-min | -0.46% | 42% | 1,101 |
| to close | -0.46% | 43% | 1,072 |
| Middle 50% of SPRY reactions | -1.54% to +0.88% |
|---|---|
| Median reaction (30-min) | -0.25% |
| Measured reactions | 1,121 |
Half of all ARS Pharmaceuticals, Inc. news events land between -1.54% and +0.88% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SPRY reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 13 | -1.56% | 23% | -1.13% |
| Coverage initiations | 17 | -0.18% | 41% | -0.36% |
| Rating reiterations | 20 | -0.06% | 35% | -0.01% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how SPRY ranks against every other measured name →
That’s how SPRY usually reacts — get an email when it moves on news →Email me when SPRY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SPRY's baseline. Nothing else.
Recent SPRY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY | Press release | PR Newswire | -0.36% | +3.87% | |
| ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY | Press release | PR Newswire | +0.98% | +1.72% | |
| Kaplan Fox Reminds ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors with Significant Losses to Seek a Leadership Role Before Deadline on October 5, 2026 | Press release | GlobeNewswire | -0.89% | -6.90% | |
| ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY | Press release | PR Newswire | +0.34% | +1.82% | |
| LAWSUIT ALERT: Investors Who Lost Over $100,000 With ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Shares - Purchased Between March and June 2026 - Should Contact the Shareholders Foundation | Press release | Business Wire | -1.42% | -5.56% | |
| ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY | Press release | PR Newswire | -0.91% | -2.00% | |
| ARS Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.68% | -0.68% | |
| ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY | Press release | PR Newswire | -2.06% | +3.09% | |
| Important Notice to Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Hub Group, Inc. (NASDAQ: HUBG); Insulet Corporation (NASDAQ: PODD); and Roblox Corporation (NYSE: RBLX): Grabar Law Office is Investigating Claims on Your Behalf | Press release | GlobeNewswire | +0.46% | +5.93% | |
| Important Notice to Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Roblox Corporation (NYSE: RBLX); Symbotic Inc. (NASDAQ: SYM); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is Investigating Claims on Your Behal | Press release | GlobeNewswire | +0.00% | -0.93% | |
| Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY): Bloom Energy Corporation (NYSE: BE); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on | Press release | GlobeNewswire | +1.23% | +2.94% | |
| Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf | Press release | GlobeNewswire | +7.84% | +10.78% | |
| ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +7.84% | +10.78% | |
| Form 10-Q ARS Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +7.84% | +10.78% | |
| Form 8-K ARS Pharmaceuticals, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +7.84% | +10.78% | |
| ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY | Press release | PR Newswire | +1.82% | — | |
| ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SPRY | Press release | Business Wire | +1.82% | — | |
| ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +1.18% | +7.48% | |
| Form 8-K ARS Pharmaceuticals, For: Jul 15 | SEC filing · Form 8-K | SEC EDGAR | +0.75% | -8.00% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating ARS Pharmaceuticals, Inc. (SPRY) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.13% | -1.04% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ARS Pharmaceuticals, Inc. (SPRY) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.26% | +0.13% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ARS Pharmaceuticals, Inc. (SPRY) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.76% | -1.40% | |
| ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | +4.52% | |
| ARS Pharmaceuticals Announces CEO Succession | Press release | GlobeNewswire | +2.83% | +6.58% | |
| Form 8-K ARS Pharmaceuticals, For: Jul 06 | SEC filing · Form 8-K | SEC EDGAR | +2.83% | +6.58% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ARS Pharmaceuticals, Inc. (SPRY) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.48% | -0.12% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating ARS Pharmaceuticals, Inc. (SPRY) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.29% | -2.91% | |
| Form 8-K ARS Pharmaceuticals, For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +3.08% | +7.15% | |
| ARS Pharmaceuticals Provides Commercial and Financial Updates | Press release | GlobeNewswire | -1.02% | +4.02% | |
| Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies | Press release | GlobeNewswire | -0.67% | +1.80% | |
| ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update | Press release | GlobeNewswire | -0.81% | +0.34% | |
| Form 10-Q ARS Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.81% | +0.34% | |
| Form 8-K ARS Pharmaceuticals, For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -0.81% | +0.34% | |
| ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President | Press release | GlobeNewswire | -0.17% | -7.72% | |
| Form 8-K ARS Pharmaceuticals, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -0.17% | -7.72% | |
| ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results | Press release | GlobeNewswire | -0.11% | -2.70% | |
| Form ARS ARS Pharmaceuticals, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.51% | +5.63% | |
| Form DEF 14A ARS Pharmaceuticals, For: Jun 24 | SEC filing · Form DEF | SEC EDGAR | +0.51% | +5.63% | |
| Form DEFA14A ARS Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | +0.51% | +5.63% | |
| neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) | Press release | GlobeNewswire | -1.33% | -2.67% | |
| ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label | Press release | GlobeNewswire | -1.98% | -5.83% | |
| ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization | Press release | GlobeNewswire | -0.21% | -3.10% | |
| Form 10-K ARS Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.21% | -3.10% | |
| Form 8-K ARS Pharmaceuticals, For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | -0.21% | -3.10% | |
| Form S-8 ARS Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | -1.52% | -2.64% | |
| ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences | Press release | GlobeNewswire | +2.00% | +2.45% | |
| ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting | Press release | GlobeNewswire | +0.71% | +1.12% | |
| EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing =15 kg to <30 kg | Press release | GlobeNewswire | -2.51% | +3.52% | |
| California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use | Press release | GlobeNewswire | +1.22% | +1.85% | |
| neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) | Press release | GlobeNewswire | +0.44% | +2.81% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SPRY section they belong to.
Where else SPRY is measured.
SPRY earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is ARS Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled SPRY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,121 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of SPRY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SPRY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.